tradingkey.logo

Telomir Pharmaceuticals Inc

TELO
查看詳細走勢圖
1.410USD
+0.040+2.92%
收盤 12/19, 16:00美東報價延遲15分鐘
47.70M總市值
虧損本益比TTM

Telomir Pharmaceuticals Inc

1.410
+0.040+2.92%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.92%

5天

-2.76%

1月

+1.44%

6月

-19.89%

今年開始到現在

-65.78%

1年

-72.78%

查看詳細走勢圖

TradingKey Telomir Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Telomir Pharmaceuticals Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在藥品行業排名131/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為。最高目標價15.50。中期看,股價處於平穩狀態。近一個月,市場表現較強,基本面評分較高,但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Telomir Pharmaceuticals Inc評分

相關信息

行業排名
131 / 158
全市場排名
483 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
15.500
目標均價
+999.29%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Telomir Pharmaceuticals Inc亮點

亮點風險
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入0.00美元
估值高估
公司最新PE估值-3.85,處於3年歷史高位
機構減倉
最新機構持股2.75M股,環比減少26.38%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉1.10M股

Telomir Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Telomir Pharmaceuticals Inc簡介

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
公司代碼TELO
公司Telomir Pharmaceuticals Inc
CEOAminov (Erez)
網址https://telomirpharma.com/

常見問題

Telomir Pharmaceuticals Inc(TELO)的當前股價是多少?

Telomir Pharmaceuticals Inc(TELO)的當前股價是 1.410。

Telomir Pharmaceuticals Inc 的股票代碼是什麼?

Telomir Pharmaceuticals Inc的股票代碼是TELO。

Telomir Pharmaceuticals Inc股票的52週最高點是多少?

Telomir Pharmaceuticals Inc股票的52週最高點是5.400。

Telomir Pharmaceuticals Inc股票的52週最低點是多少?

Telomir Pharmaceuticals Inc股票的52週最低點是1.120。

Telomir Pharmaceuticals Inc的市值是多少?

Telomir Pharmaceuticals Inc的市值是47.70M。

Telomir Pharmaceuticals Inc的淨利潤是多少?

Telomir Pharmaceuticals Inc的淨利潤為-16.53M。

現在Telomir Pharmaceuticals Inc(TELO)的股票是買入、持有還是賣出?

根據分析師評級,Telomir Pharmaceuticals Inc(TELO)的總體評級為--,目標價格為15.500。

Telomir Pharmaceuticals Inc(TELO)股票的每股收益(EPS TTM)是多少

Telomir Pharmaceuticals Inc(TELO)股票的每股收益(EPS TTM)是-0.367。
KeyAI